Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 650 across all filing types
Latest filing 2023-03-20 Director's Dealing
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service and Korea Exchange. This is a standard regulatory filing in South Korea used to disclose insider trading or changes in shareholdings by company directors and major shareholders. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2023-03-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when a major shareholder or executive changes their stake in a company. This corresponds to the 'Director's Dealing' (DIRS) category, as it details the shareholding changes of a major shareholder (Gem & Company) in the issuer (GemVax & Kael).
2023-03-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when a shareholder's stake crosses certain thresholds (typically 5%). This document details the shareholding status, changes in ownership, and contractual relationships (pledges, loans) of the major shareholder (Gem & Company) and its special related parties in GemVax & Kael. This falls under the 'Major Shareholding Notification' category.
2023-03-20 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) announcing a significant change (over 30%) in revenue or profit/loss structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial changes. Since it provides specific financial highlights and explanations for the variance rather than just announcing the availability of a report, it falls under the 'Earnings Release' category as it serves as the initial announcement of financial performance results. FY 2022
2023-03-15 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company 'GemVax'. It outlines the date, location, agenda items (including financial statement approval, director appointments, and remuneration limits), and details regarding electronic voting. This document is a standard proxy solicitation material sent to shareholders to inform them of the upcoming meeting and request their participation/votes, which fits the definition of a Proxy Solicitation & Information Statement.
2023-03-15 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing titled '주주총회 집중일 개최 사유 신고' (Report on the reason for holding a general meeting on a concentrated date). It is a specific regulatory disclosure required by the KOSDAQ exchange when a company holds its shareholder meeting on a date where many other companies are also holding theirs. Since it does not fit into the specific categories of AGM materials, proxy statements, or dividend announcements, and is a standard regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2023-03-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.